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Abstract
Mammalian prions, transmissible agents causing lethal neurodegenerative diseases, are composed 
of assemblies of misfolded cellular prion protein (PrP) 1. A novel PrP variant, G127V, was under 
positive evolutionary selection during the epidemic of kuru, an acquired prion disease epidemic of 
the Fore population in Papua New Guinea, and appeared to provide strong protection against 
disease in the heterozygous state2. We have now investigated the protective role of this variant and 
its interaction with the common worldwide M129V PrP polymorphism; V127 was seen exclusively 
on a M129 PRNP allele. Here we demonstrate that transgenic mice expressing both variant and 
wild type human PrP are completely resistant to both kuru and classical CJD prions (which are 
closely similar) but can be infected with variant CJD prions, a human prion strain resulting from 
exposure to BSE prions to which the Fore were not exposed. Remarkably however, mice 
expressing only PrP V127 were completely resistant to all prion strains demonstrating a different 
molecular mechanism to M129V, which provides its relative protection against classical CJD and 
kuru in the heterozygous state. Indeed this single amino acid substitution (G→V) at a residue 
invariant in vertebrate evolution is as protective as deletion of the protein. Further study in 
transgenic mice expressing different ratios of variant and wild type PrP indicates that not only is 
PrP V127 completely refractory to prion conversion, but acts as a potent dose-dependent inhibitor 
of wild type prion propagation.
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Prions cause fatal neurodegenerative conditions such as scrapie in sheep, bovine spongiform 
encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans1. The 
fundamental molecular process, seeded propagation of assemblies of misfolded host protein, 
is increasingly recognised as being of importance in all the major human neurodegenerative 
diseases3. There is a common polymorphism, present worldwide, in the substrate protein in 
human prion disease, human prion protein (PrP), where either methionine (M) or valine (V) 
is present at residue 129. MV heterozygosity provides relative protection against acquired, 
sporadic, and some inherited prion diseases4-6 and may have been selected during the 
evolution of modern humans by ancestral prion disease epidemics7. This protective effect is 
thought to relate to inhibition of homotypic protein-protein interactions5, 8 although residue 
129 also influences the propagation of particular prion strains via conformational 
selection9, 10. Heterozygosity at another polymorphism, E219K, also provides resistance to 
CJD in Japan11.
Kuru was a devastating epidemic prion disease transmitted by endocannibalism and 
restricted to a remote area in Papua New Guinea (PNG). We reported a novel PrP variant 
(G127V) amongst unaffected individuals which appeared be a resistance factor selected by 
the epidemic and unique to this region2. Given the proximity to residue 129, we considered 
that it may have a similar action to M129V, blocking homotypic interactions and exerting its 
protective effect only in the heterozygous state. No PRNP codon 127VV homozygotes were 
identified in the kuru-exposed population and V127 was always seen on an M129 allele2. We 
therefore generated multiple lines of transgenic mice, expressing only human PrP (HuPrP) 
on a congenic FVB/N Prnpo/o background, to investigate whether G127V was indeed 
protective and whether this protection was dependent on heterozygosity or was an intrinsic 
property of the variant protein. Additionally we investigated its interaction with the residue 
129 polymorphism.
Two lines of transgenic mice homozygous for HuPrP V127 were studied: Tg(HuPrP 
V127M129/V127M129 Prnpo/o)-183 (V127M129 Tg183) and Tg(HuPrP V127M129/V127M129 
Prnpo/o)-190 (V127M129 Tg190). PrP expression levels in homozygotes as compared to 
pooled normal human brain were 2-fold for V127M129 Tg183 and 1-fold for V127M129 
Tg190. G127V heterozygous mice were derived by crossing these lines with FVB-congenic 
versions of Tg35 mice homozygous for HuPrP G127M129 12-15 or Tg152 mice homozygous 
for HuPrP G127V129 15-19 designated Tg(HuPrP G127M129/G127M129 Prnpo/o)-35c 
(G127M129 Tg35c) and Tg(HuPrP G127V129/G127V129 Prnpo/o)-152c (G127V129 Tg152c) 
respectively. G127M129 Tg35c and G127V129 Tg152c express wild type huPrP at 2- and 6-
times respectively as compared to pooled normal human brain (table 1). Extended Data Fig.
1 shows relative PrPC expression levels in all transgenic mice used in this study.
All transgenic lines were then challenged by intracerebral prion inoculation from well-
characterised and previously transmitted human prion disease cases including all three 
PRNP codon 129 genotypes and comprising four cases of kuru, 12 cases of classical CJD 
and two cases of variant CJD (vCJD). Heterozygous HuPrP G127M129/V127M129 mice 
(Tg35c × Tg183 and Tg35c × Tg190) (table 1), having the genotype associated with disease 
resistance in the kuru-exposed human population, proved completely resistant to all four 
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kuru isolates (which included all three PRNP codon 129 genotypes and two molecular strain 
types) (Fig. 1a and table 2a) while mice expressing wild type HuPrP G127M129/G127M129 
(Tg35c) (Fig. 1a, table 2a) or G127V129/G127V129 (Tg152c) (table 2b) were fully susceptible 
with 100% attack rates. This is consistent with the population genetic data suggesting kuru 
resistance of G127V individuals. We have previously reported that prion strains seen in kuru 
brain are indistinguishable from those seen in classical CJD patients19. Similarly, none of 
four classical CJD isolates from patients of PRNP genotype 129MM transmitted to either 
line of G127M129/V127M129 mice (table 2a and Fig. 1b), while all four transmitted uniformly 
to Tg35c mice expressing wild type huPrP (Fig. 1b and table 2a). Remarkably, however, 
occasional G127M129/V127M129 mice developed clinical disease, and a larger number 
showed evidence of subclinical infection (positive PrP immunohistochemistry and/or 
western blot for PrPSc), on challenge with vCJD prions (table 2d and Extended Data Fig. 2). 
vCJD is a novel BSE-derived prion strain17, 20, 21 to which the population in the kuru-
affected area of PNG were not exposed.
The key question with respect to whether the protective effect of V127 is via a similar 
mechanism to the M129V polymorphism was addressed by challenge of mice homozygous 
for HuPrP V127M129. While mice homozygous for wild type HuPrP G127M129 or G127V129 
are both highly susceptible to CJD prions, remarkably mice homozygous for HuPrP 
V127M129 were completely resistant to all 18 human prion disease isolates, including vCJD 
prions, with no clinical transmissions or evidence of subclinical infection (Fig. 1a and b, 
table 3 and Extended Data Fig. 3).
We also challenged mice heterozygous at both residues 127 and 129 of HuPrP (G127V129/
V127M129) produced by crossing Tg183 or Tg190 mice with Tg152c mice (tables 1 and 2B). 
The higher level of expression of HuPrP V129 in Tg152c mice as compared to the other lines 
meant that there was a marked difference in the ratio of expression of the variant (V127M129) 
and wild type (G127V129) HuPrP in these crosses (table 1). While Tg183 and Tg35c had 
closely similar levels of expression of V127M129 and G127M129 HuPrP respectively, such 
that the Tg35c × Tg183 cross closely modelled the human PRNP G127V genotype, the 
expression ratios of wild type G127V129 to variant V127M129 HuPrP were approximately 6:1 
and 3:1 for the Tg152c × Tg190 and Tg152c × Tg183 crosses respectively (table 1, 
Extended Data Fig.1 and 4). Interestingly, in these crosses some transmissions of kuru and 
classical CJD prions were seen (table 2b, Extended Data Fig. 4 and 5). In the Tg152c × 
Tg183 crosses, with a 3-fold excess of wild type PrP, subclinical infections were seen with 
four out of the 12 isolates used, and one kuru isolate (I10336) was associated with clinical 
disease (table 2b). However with the Tg152c × Tg190 crosses, with a 6-fold excess of wild 
type PrP, transmissions were seen from all isolates, the majority resulting in clinical disease 
(table 2b).
To further investigate the effect of HuPrP V127 on prion propagation, we compared 
hemizygous Tg(HuPrP G127V129 Prnpo/o)-152c mice with the Tg152c × Tg183 and Tg152c 
× Tg190 crosses (table 2c). The hemizygous line was challenged with two classical CJD and 
one kuru isolate that had resulted in a 100% attack rate in both crosses. Again, 100% attack 
rates were seen for all three isolates but the incubation periods were significantly shorter (P< 
0.0001; table 2c) in the absence of HuPrP V127 than in either cross. These data, together 
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with comparison of the two crosses themselves (table 2b), are consistent with a dominant 
negative effect of HuPrP V127 expression. Although dominant negative inhibition has been 
reported for other natural polymorphic residues of mammalian PrP in transgenic mice22-24 
none have shown complete prevention of prion conversion when expressed at a 1:1 ratio 
with wild type PrP. Dominant negative effects on yeast prion propagation have also been 
reported25.
Our transgenic modelling of the HuPrP G127V polymorphism demonstrates that it confers 
strong protection against prion disease in the heterozygous state. However, most 
importantly, the molecular basis of this effect is clearly distinct from that proposed for the 
well-established HuPrP M129V polymorphism which is protective against developing 
sporadic CJD only in the heterozygous state: inhibition of homotypic protein-protein 
interactions during the process of prion propagation. Here we demonstrate that HuPrP V127 
is intrinsically resistant to prion conversion and indeed capable of inhibiting propagation of 
wild type prions in a dose-dependent manner. Mice expressing only HuPrP V127 appear as 
resistant to prion disease as PrP null mice26 and understanding the structural basis of this 
effect may therefore provide critical insight into the molecular mechanism of mammalian 
prion propagation.
At its height when first recognised by Western medicine in 1957, kuru was a devastating 
epidemic largely affecting women and children and killing up to 2% of the population 
annually in some villages. Indeed some villages became largely devoid of young women of 
childbearing age. While collapse of the Fore population was prevented by cessation of 
endocannibalism in the late 1950s which interrupted the route of transmission and led to a 
gradual decline in incidence27, our data suggest that if transmission had continued the 
epicentre of the affected region might have been repopulated with kuru-resistant individuals 
as a population genetic response to the epidemic. Understanding the structural basis of why 
HuPrP V127 is unable to propagate prions of multiple strain types may provide key insights 
into prion propagation and the development of rational therapeutics.
Methods
Ethics Statement
Storage and biochemical analyses of post-mortem human brain samples and transmission 
studies to mice were performed with written informed consent from patients with capacity to 
give consent. Where patients were unable to give informed consent, assent was obtained 
from their relatives in accordance with UK legislation and Codes of Practice. Samples were 
stored and used in accordance with the Human Tissue Authority Codes of Practice and in 
line with the requirements of the Human Tissue Authority licence held by UCL Institute of 
Neurology. This study was performed with approval from the Medical Research Advisory 
Committee of the Government of Papua New Guinea, the National Hospital for Neurology 
and Neurosurgery and the UCL Institute of Neurology Joint Research Ethics Committee 
(now National Research Ethics Service Committee, London – Queen Square) - REC 
references: 03/N036, 03/N038 and 03/N133. Work with mice was performed under approval 
and licence granted by the UK Home Office (Animals (Scientific Procedures) Act 1986); 
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Project Licence number 70/6454 which conformed to University College London 
institutional and ARRIVE guidelines (www.nc3rs.org.uk/ARRIVE/).
Generation of transgenic mice
The 759bp human PrP ORF was amplified by PCR with pfu polymerase from genomic 
DNA prepared from the brain of a patient with the 127V polymorphism on the 129M allele, 
using forward primer 5′-GTCGACCAGTCATTATGGCGAACCTT-3′ and reverse primer 
5′-CTCGAGAAGACCTTCCTCATCCCACT-3′. Restriction sites Sal I and Xho I 
(underlined) were introduced in the forward and reverse primers respectively for cloning. 
The blunt ended PCR fragment generated by pfu polymerase was subcloned into Sma I 
digested pSP72 vector and sequenced to ensure that no spurious alterations had been 
introduced by the PCR and to confirm the presence of valine-127 and methionine-129 
polymorphisms matching the patient DNA template. The amplified human PrP ORF with 
the confirmed polymorphisms was then isolated by Sal I and Xho I digestion. Subsequent 
subcloning into the Sal I site of the cosmid vector SHaCosTt, packaging and preparation of 
high quality DNA of the Not I transgene insert was as previously reported12. Microinjection 
of the purified Not I DNA fragment was carried out according to standard protocol into 
single cell eggs of Prnp null mice which had been backcrossed onto an FVB/N genetic 
background. Genotyping was performed by PCR and PrP expression levels estimated by 
western blot analysis as previously reported 12, 29. Two homozygous lines were established 
for variant HuPrP V127M129 described as Tg(HuPrP V127M129/V127M129 Prnpo/o)-183 
(V127M129 Tg183) and Tg(HuPrP V127M129/V127M129 Prnpo/o)-190 (V127M129 Tg190), 
with transgene expression levels of 2 and 1 × respectively, that of pooled 10% (w/v) normal 
human brain homogenate (table 1). FVB-congenic versions of Tg35 mice homozygous for 
HuPrP G127M129 12-15 and Tg152 mice homozygous for HuPrP G127V129 15-19 were used as 
wild type human PrP-expressing controls, designated Tg(HuPrP G127M129/G127M129 
Prnpo/o)-35c (G127M129 Tg35c) and Tg(HuPrP G127V129/G127V129 Prnpo/o)-152c 
(G127V129 Tg152c) respectively. The PRNP codon 127-129 genotypes and relative 
expression levels of wild type and variant PrP in the parental transgenic lines and in the F1 
crosses are shown in table 1.
Transmission Studies
Strict bio-safety protocols were followed. Inocula were prepared, using disposable 
equipment for each inoculum, in a microbiological containment level 3 laboratory and 
inoculations performed within a class 1 microbiological safety cabinet as described 
previously12, 19. Ten mice per group of control G127M129 Tg35c and G127V129 Tg152c lines 
and 15 per group of newly generated V127M129 Tg183, V127M129 Tg190 lines and their 
respective crosses with Tg35c and Tg152c, were inoculated (see below) with human brain 
homogenates from neuropathologically confirmed patients comprising, four kuru cases, 
eight sporadic CJD cases, four iatrogenic CJD cases and two cases of vCJD. The genotype 
of each mouse was confirmed by PCR of ear punch DNA prior to inclusion and all mice 
were uniquely identified by sub-cutaneous transponders. Disposable cages were used and all 
cage lids and water bottles were also uniquely identified by transponder and remained with 
each cage of mice throughout the incubation period. Care of the mice was according to 
institutional guidelines. Mice (female, aged 6-8 weeks) were randomly assigned to 
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experimental groups and anaesthetised with a mixture of halothane and O2, and 
intracerebrally inoculated into the right parietal lobe with 30 μl of a 1% (w/v) brain 
homogenate prepared in Dulbecco’s phosphate buffered saline lacking Ca2+ or Mg2+ ions 
(D-PBS). All mice were thereafter examined daily for early indicators of clinical prion 
disease including piloerection, sustained erect ears, intermittent generalised tremor, 
unsustained hunched posture, rigid tail, mild loss of coordination,and clasping hind legs 
when lifted by the tail. Definite diagnosis of clinical prion disease (triggering experimental 
end point) was reached if mice exhibited any two early indicator signs in addition to one 
confirmatory sign, or any two confirmatory signs. The confirmatory signs included 
ataxia,impairment of righting reflex, dragging of hind limbs, sustained hunched posture, or 
significant abnormal breathing. Mice were killed (by CO2 asphyxiation) if they exhibited 
any signs of distress or once a diagnosis of prion disease was established. At post-mortem 
brains from inoculated mice were removed, divided sagittally with half frozen and half fixed 
in 10% buffered formol saline. Subsequent immunohistochemical or biochemical 
investigations were performed blind to sample provenance.
Neuropathology and Immunohistochemistry
Fixed brain was immersed in 98% formic acid for 1 hour and paraffin wax embedded. Serial 
sections of 4 μm thickness were pre-treated by boiling for 10 min in a low ionic strength 
buffer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8) before exposure to 
98% formic acid for 5 min. Abnormal PrP accumulation was examined using anti-PrP 
monoclonal antibody ICSM 35 (D-Gen Ltd, London) on a Ventana automated 
immunohistochemical staining machine (Ventana Medical Systems Inc., Tucson, Arizona) 
using proprietary secondary detection reagents (Ventana Medical Systems Inc) before 
development with 3′3 diaminobenzedine tetrachloride as the chromogen30. Harris 
haematoxylin and eosin staining was done by conventional methods. Appropriate controls 
were used throughout.
Immunoblotting
Preparation of brain homogenates (10% (w/v) in D-PBS), proteinase K digestion (75 μg/ml 
for 1 h at 37°C) and subsequent immunoblotting was performed as described 
previously28, 30. Blots were probed with anti-PrP monoclonal antibody ICSM 35 (D-Gen 
Ltd, London) in conjunction with an anti-mouse IgG-alkaline phosphatase conjugate and 
development in chemiluminescent substrate (CDP-Star; Tropix Inc). Primary screening of 
brain homogenates was performed blind to sample identity.
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Extended Data Figure 1. Immunoblots showing relative PrPC expression levels in transgenic 
mice
The provenance of each brain sample is designated above each lane and molecular markers 
are indicated on the left. The PRNP codon 127 (G, glycine, V, valine) or codon 129 (M, 
methionine, V, valine) genotypes of the transgenic mice are designated below. Transgenic 
mouse brains were analysed by enhanced chemiluminescence without proteinase-K 
digestion and equal amounts of total protein loaded in each well and probed with anti-PrP 
monoclonal antibody ICSM 35. Wild type human PrP expression levels of G127M129/
G127M129 Tg35c and G127V129/G127V129 Tg152c mice are 2- and 6-fold higher 
respectively, than seen in 10 % (w/v) pooled human brain homogenate. Homozygous 
V127M129 Tg183 and Tg190 mice have 2-fold higher or equivalent PrP expression levels 
respectively compared to 10 % (w/v) pooled human brain homogenate.
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Extended Data Figure 2. Immunohistochemical analysis of transgenic mouse brain following 
challenge with vCJD prions
All mice were intracerebrally challenged with the same vCJD prion isolates (I342 and 
I7042). Abnormal PrP deposition in fixed post-mortem brain from affected mice was 
detected using anti-PrP monoclonal antibody ICSM 35. (a-b) Homozygous Tg35c mice 
(expressing G127M129/G127M129 wild type PrP only) show intense and widespread PrP 
plaque deposits. Magnified areas show (ai) hippocampus, (bi) frontal cortex and (aii and bii) 
thalamus. In contrast, heterozygous G127M129/V127M129 Tg35c/Tg183 mice expressing 
equivalent levels of G127M129 and V127M129 PrP (c-d) show only weak PrP deposition in 
the corpus callosum (ci and di) with no abnormal PrP deposition detected in other brain 
areas, for example, in the thalamus (cii and dii). Heterozygous G127M129/V127M129 Tg35c/
Tg190 mice which express a lower level of V127M129 PrP relative to wild type G127M129 
PrP (e-f) show greater levels of PrP deposition than seen in Tg35c/Tg183 mice following 
challenge with the same vCJD prion isolates, (ei, eii and fi) corpus callosum; (fii) pons. 
Scale bar, upper panels (a-f) 2 mm; magnified panels, 100 μm.
Asante et al. Page 8









Extended Data Figure 3. Immunohistochemical analysis of homozygous PRNP V127M129/
V127M129 transgenic mouse brain following challenge with human prions
Mice were intracerebrally challenged with kuru, classical and variant CJD prions. Following 
prolonged (>600 days) post inoculation periods, abnormal PrP deposition in fixed post-
mortem brain was examined using anti-PrP monoclonal antibody ICSM 35. (a-d) 
V127M129/V127M129 Tg183 mice with 2-fold overexpression of V127M129 PrP. (E-H) 
V127M129/V127M129 Tg190 mice expressing endogenous levels of V127M129 PrP. Red 
square boxes in the main panels (a-h) define the area of magnified images of hippocampus 
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(i) and thalamus (ii) shown in the lower panels. Scale bar, a-h, 2 mm; magnified panels i and 
ii, 100 μm. The lack of detection of abnormal PrP deposition in brain indicates that the mice 
are not subclinically infected with prions.
Extended Data Figure 4. Schematic diagram summarising transmissions of kuru and classical 
CJD prions to transgenic mice expressing human PrP
G127M129/G127M129 Tg35c mice or G127V129/G127V129 Tg152c mice are homozygous for 
wild type human PrP alleles and are fully susceptible to kuru and classical CJD prions. 
V127M129/V127M129 Tg183 or V127M129/V127M129 Tg190 transgenic mice are homozygous 
for the variant V127M129 allele found only in humans from the kuru-exposed population of 
Papua New Guinea and are entirely resistant to infection with kuru and classical CJD prions. 
The levels of PrP expression in the brain of these homozygous transgenic mice relative to a 
pooled human brain homogenate are 1× (Tg190 mice) 2× (Tg35c and Tg183 mice) and 6× 
(Tg152c mice). Generation of F1 mice through inter-breeding the various homozygous lines 
produces different combinations of the various human PrP alleles leading to differences in 
the relative expression levels of the various prion proteins in brain. The PrP expression 
ratios from the two PrP alleles in the crosses are shown in parentheses above the cartoon 
mice. Full, intermediate or low susceptibility of the mice to infection with kuru and classical 
CJD prions is indicated by three, two or one diagonal red bar, respectively, drawn across the 
mice. Mice with no red bar are entirely resistant to infection with kuru and classical CJD 
prions.
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Extended Data Figure 5. Immunohistochemical analysis of homozygous PRNP G127V129/
G127V129 and heterozygous G127V129/V127M129 transgenic mouse brain following challenge 
with human prions
Mice were intracerebrally challenged with kuru and classical CJD prions and abnormal PrP 
deposition in fixed post-mortem brain from affected mice was examined using anti-PrP 
monoclonal antibody ICSM 35. Red square boxes labelled i and ii in panels a-f mark brain 
areas that are magnified and displayed below; (i) cortex and (ii) thalamus. (a-b) Wild type 
G127V129/G127V129 Tg152c mice. (c-d) Heterozygous G127V129/V127M129 Tg152c/Tg183 
mice. (e-f) Heterozygous G127V129/V127M129 Tg152c/190 mice Scale bar, a-f, 2 mm; 
magnified panels i and ii, 100 μm. The detection of abnormal PrP deposition in brain 
indicates that the mice are infected with prions.
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Figure 1. Transmission rates of human prions to transgenic mice homo- or heterozygous for 
human PrP V127
Transgenic mice were intracerebrally inoculated with brain homogenate from patients with 
kuru (a) or classical CJD (b). Codon 127 and 129 PRNP genotypes of the recipient mice are 
shown (G, glycine, M, methionine, V, valine). G127M129 is a wild type human allele, and the 
V127M129 allele is seen only in humans from the kuru-exposed population of Papua New 
Guinea. Attack rate reports the total of clinically affected and sub-clinically infected mice as 
a proportion of the number of inoculated mice after prolonged (>600 days) post-inoculation 
periods. Primary prion transmission data are reported in tables 2 and 3.
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Table 1
Transgenic mice expressing G127 and V127 human PrP
Transgenic mice




WT† G127 allele 
expression level (x)





Tg35c G127M129/G127M129 2 2 - -
Tg152c G127V129/G127V129 6 6 - -
Tg183 V127M129/V127M129 2 - 2 -
Tg190 V127M129/V127M129 1 - 1 -
F1 crosses:
Tg35c × Tg183 G127M129/V127M129 2 1 1 1 : 1
Tg35c × Tg190 G127M129/V127M129 1.5 1 0.5 2 : 1
Tg152c × Tg183 G127V129/V127M129 4 3 1 3 : 1
Tg152c × Tg190 G127V129/V127M129 3.5 3 0.5 6 : 1
Tg152c +/o (Hemi)§ G127V129 3 3 - -
WT = wild type
*
PrP expression level is relative to pooled 10% (w/v) normal human brain homogenate
†Wild type alleles are either G127M129 or G127V129
‡Variant allele is V127M129
§Generated by crossing Tg152c with FVB/PrP-null mice
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Table 2
Transmission of human prions to transgenic mice heterozygous for human PrP V127
Inoculum Transmission data

















Tg35c × Tg183 
G127M129/V127M129
Tg35c × Tg190 
G127M129/V127M129
kuru I516 T3 VV 14/14
509 ± 56 
(3) 0/11 >518-605 0/13 >517-605
kuru I520 T3 VV 12/12 558 ± 4 (4) 0/14 >525-622 0/14 >460-622
kuru I10336 T3 MV 13/13
454 ± 14 
(10) 0/14 >522-606 0/11 >504-607
kuru I518 T2 MM 11/11
493 ± 32 
(7) 0/12 >545-620 0/13 >544-603
iCJD (GH) I035 T1 MM 10/10
221 ± 3 
(10) 0/10 >462-603 0/8 >506-602
sCJD I11058 T1 MM 8/8 231 ± 3 (8) 0/8 >467-605 0/7 >487-605
iCJD (DM) I026 T2 MM 10/10 256 ± 9 (8) 0/8 >507-601 0/7 >520-602
sCJD I7040 T2 MM 10/10
233 ± 3 
(10) 0/8 >582-604 0/7 >600-604
B Tg152c G127V129/G127V129
Tg152c × Tg183 G127V129/
V127M129
Tg152c × Tg190 G127V129/
V127M129
kuru I516 T3 VV 9/9 218 ± 1 (6) 0/13 >447-608 9/15 543, 592
kuru I520 T3 VV 9/9 196 ± 7 (7) 0/18 >491-616 13/13 498 ± 17 (5)
kuru I10336 T3 MV 15/15 212 ± 3 (11) 15/15 456 ± 3 (15) 15/15 316 ± 4 (14)
kuru I518 T2 MM 11/11 211 ± 4 (8) 3/11 >494-620 13/14 468 ± 13 (9)
sCJD I280 T2 VV 8/8 203 ± 5 (4) 0/4 >600-602 10/10 559 ± 14 (8)
sCJD I278 T2 VV 6/6 236 ± 8 (6) 0/8 >424-602 8/9 582
sCJD I284 T2 MV 9/9 338 ± 4 (8) 0/9 >410-602 5/7 >545-608
sCJD I1478 T2 MV 10/10 248 ± 8 (8) 0/6 >451-608 2/7 >482-603
sCJD I7394 T3 VV 9/9 213 ± 1 (8) 7/7 >537-677 10/10 427 ± 8 (10)
sCJD I764 T3 MV 10/10 219 ± 5 (7) 9/10 >368-588 10/10 461 ± 7 (9)
iCJD (GH) I2651 T3 VV 8/8 200 ± 3 (6) 0/6 >567-607 7/7 538 ± 2 (5)
iCJD (GH) I020 T3 MV 9/9 211 ± 2 (6) 7/7 >489-602 10/10 399 ± 8 (9)
C
Tg152c × Tg183 G127V129/
V127M129
Tg152c × Tg190 G127V129/
V127M129 Tg152c+/o (Hemi) G127V129
iCJD (GH) I020 T3 MV 7/7 >489-602 10/10 399 ± 8‡ (9) 14/14 252 ± 3‡ (14)
sCJD I7394 T3 VV 7/7 >537-677 10/10 427 ± 8‡ (10) 12/12 245 ± 5‡ (12)
kuru I10336 T3 MV 15/15 456 ± 3 (15) 15/15 316 ± 4‡ (14) 15/15 222 ± 2‡ (15)
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D Tg35c G127M129/G127M129 Tg35c × Tg183 G127M129/V127M129 Tg35c × Tg190 G127M129/V127M129
vCJD I342 T4 MM 15/15 >426-603 9/15 467, 556 17/18 419±17 (3)
vCJD I7042 T4 MM 14/14 559, 561 4/13 >496-607 10/12 596
iCJD, iatrogenic CJD; sCJD, sporadic CJD; GH, growth hormone; DM, dura mater
*According to classification of Hill et al.28
†Attack rate is defined as the total number of both clinically affected and sub-clinically infected mice as a proportion of the total number of 
inoculated mice. Sub-clinical prion infection was assessed by immunoblotting and/or immunohistochemical examination of brain. Incubation 
periods are reported for clinically affected mice in days; where n ≥ 3 the mean ± SEM is reported with the number of mice contributing to the mean 
shown in parentheses, otherwise individual incubation times are given. In groups where no clinical transmission of prion disease was observed, the 
attack rate represents subclinical infection only and the interval between inoculation and death (from either senescence, culling due to inter-current 
illness or termination of the experiment) is reported as >x-y days.
‡
Mean incubation periods for all 3 isolates are significantly lower in Tg152c hemizygotes than in Tg190 × Tg152c heterozygotes (P<0.0001; two-
tailed unpaired t-test).
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Table 3
Transmission of human prions to transgenic mice homozygous for human PrP V127
Inoculum Transmission data
Aetiology Source Code Human PrPSc type* Attack rate†
Incubation period, 
(days p.i) Attack rate†
Incubation period, 
(days p.i)
Tg183 V127M129/V127M129 Tg190 V127M129/V127M129
kuru I516 T3 VV 0/19 >488-604 0/22 >391-609
kuru I520 T3 VV 0/19 >391-609 0/19 >370-609
kuru I10336 T3 MV 0/21 >405-607 0/24 >463-617
kuru I518 T2 MM 0/12 >439-600 0/13 >432-603
vCJD I342 T4 MM 0/8 >553-605 0/10 >506-604
vCJD I7042 T4 MM 0/11 >522-609 0/14 >446-607
iCJD (GH) I035 T1 MM 0/10 >434-622 0/10 >450-602
sCJD I11058 T1 MM 0/8 >411-609 0/9 >454-612
iCJD (DM) I026 T2 MM 0/9 >381-602 0/8 >516-602
sCJD I7040 T2 MM 0/8 >524-601 0/6 >564-600
sCJD I280 T2 VV 0/9 >532-602 0/9 >425-601
sCJD I278 T2 VV 0/7 >530-602 0/7 >417-601
sCJD I284 T2 MV 0/6 >549-603 0/6 >466-609
sCJD I1478 T2 MV 0/7 >517-602 0/7 >418-617
sCJD I7394 T3 VV 0/8 >500-600 0/8 >600-603
sCJD I764 T3 MV 0/10 >447-602 0/8 >484-607
iCJD (GH) I2651 T3 VV 0/7 >563-606 0/7 >487-599
iCJD (GH) I020 T3 MV 0/6 >546-603 0/6 >572-600
(days p.i), days post inoculation; vCJD, variant CJD; sCJD, sporadic CJD; iCJD, iatrogenic CJD; GH, growth hormone; DM, dura mater
*According to classification of Hill et al.28
†Attack rate is defined as the total of clinically affected and sub-clinically infected mice as a proportion of the number of inoculated mice. Sub-
clinical prion infection was assessed by immunoblotting and/or immunohistochemical examination of brain. As no clinical transmission of prion 
disease was observed the interval between inoculation and death (from either senescence, culling due to inter-current illness or termination of the 
experiment) is reported as >x-y days.
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